Ryvu Therapeutics
Ryvu Therapeutics is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
An Open-Label, Single Agent, Phase I/II Trial Investigating the Safety and Efficacy of RVU120 (SEL120) in Patients with Relapse / Refractory Metastatic or Advanced Solid Tumors
Sponsor Ryvu Therapeutics S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available2 trial-level findings · Read insights
- The trial involved seven principal investigators across Spain and Poland.
- Following review of Part 1 preliminary efficacy data and the overall development program, the sponsor proceeded only with Part 2 Group E, including the food-effect substudy; the Part 2 efficacy-expansion groups were not initiated.
These findings describe the trial, not the service provider’s performance or responsibility.
A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of RVU120 in Combination with Venetoclax in Participants with Acute Myeloid Leukemia Who Failed Prior Therapy with Venetoclax and a Hypomethylating Agent (RIVER-81)
Sponsor Ryvu Therapeutics S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
An Open Label, Phase 2 Clinical Trial of MEN1703 as Monotherapy and in Combination with Glofitamab in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Sponsor Ryvu Therapeutics S.A.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia with or without NPM1 Mutation (RIVER-52)
Sponsor Ryvu Therapeutics S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
An Open-Label Clinical Trial of RVU120 as Monotherapy and in Combination with Ruxolitinib in Patients with Intermediate or High-Risk, Primary or Secondary Myelofibrosis (POTAMI-61)
Sponsor Ryvu Therapeutics S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Ryvu Therapeutics?
The 2026-10-09 snapshot links Ryvu Therapeutics to 5 distinct CTIS trials. Recorded services include Statistical analysis, Biomarker analysis, Laboratory services, pharmacodynamic biomarkers: plasma cytokines and pSTAT proteins analysis. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Ryvu Therapeutics?
The most frequently recorded therapeutic areas are Haematological Malignancies, Solid Tumor Oncology. Recorded phases include Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Ryvu Therapeutics conducted?
The linked trials record locations in 5 countries, including Poland, Spain, France, Italy, Germany. These are trial locations, not confirmed office locations or countries where Ryvu Therapeutics delivered services.
What can this page tell me about Ryvu Therapeutics's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Ryvu Therapeutics. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Ryvu Therapeutics S.A.